This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

Santa Ana, CA

Saint Joseph, MO

Derm Center

Fort Smith, AR

Arlington, TX

Texas Medical Center

Novartis

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Nagoya City University Hospital

Tartu, Estonia

Benowa, Australia

Szolnok, Hungary

Leipzig, Germany

Kelowna, Canada

Hannover, Germany

Vida Dermatology South

 Edmonton, Canada

Portland, OR

Calgary, Canada

Clinical Trial Center

Remscheid, Germany

Carlton, Australia

Clinical Research Institute of Southern Oregon (CRISOR)

Maldegem, Belgium

Kortrijk, Belgium

Saskatoon, Canada

Haematology Department

Boise, ID

Sacramento, CA

Dublin, CA

Reno - Moana Lane Location

Bakersfield, CA

Canoga Park, California

Northridge, CA

Santa Monica, CA

Los Angeles, CA

Long Beach, CA

Las Vegas, NV

Rapid City, SD

Scottsdale, AZ

Albuquerque, NM

Lincoln, NE

Clinical Research Unit

Dermatology and Skin Cancer Center Leawood

Ottawa, Canada

St. Johns, NL

Clinical Operations Department

Newmarket, Canada

Richmond Hill, Canada

Richmond Hill, CA

Ontario, CA

Ontario, Canada

Waterloo, Canada

Ajax, Canada

Troy, MI

Etobicoke, Canada

Toronto, Canada

Mississauga, Canada

Oakvile, Canada

Burlington, Canada

Hamilton, Canada

Windsor, Canada

Niagara Falls, Canada

West Lafayette, Indiana

Oklahoma City, OK

SLUCare Academic Pavilion - Endocrinology Division Research

Indianapolis, IN

Bexley, OH

Plano, TX

Department of Cardiology

Hot Springs, AR

North Little Rock

Camp Hill, PA

Jose Garcia, Coordinator

New York, NY

Forest Hills Dermatology Group

Towson, MD

Chevy Chase, MD

San Antonio, TX

San Antonio, Texas

Bellaire, TX

McGovern Medical School - ACTAT - Research Department

Internal Medicine Glennan Center for Geriatrics and Gerontology

Charlotte, NC

Research Center

Boca Raton, FL

Miami Lakes, FL

Hialeah, FL

Miami, FL

Coral Gables, FL

San Juan, PR

Santiago, Chile

Rosario, Argentina

Buenos Aires, Argentina

Amgen

A Multicenter, Randomized, Single-Blind, Phase Ⅱ Clinical Trial and Open Label Long-term Observation Study of ADSTEM Inj. to Evaluate the Safety and Efficacy in Patients with Moderate to Severe Subacute and Chronic Atopic Dermatitis.

The aim of this study is to evaluate the safety and efficacy of ADSTEM Inj. against Placebo in the treatment of atopic dermatitis in patients with moderate to severe acute and chronic atopic.

Safety and Efficacy in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis

EHL Bio

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy and safety of upadacitinib at different doses in adult participants with moderate to severe AD.

Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD). This study is conducted in 2 periods. During Period 1, participants are randomly assigned into 1 of 2 groups called treatment arms to receive upadacitinib 15mg or dupilumab 300mg. Based on the participants response to upadacitinib 15mg, they may have their dose increased to upadacitinib 30mg after 2 weeks. In Period 2, participants that completed Period 1 will either remain on their assigned dose or be reassigned to a different dose based on their Eczema Area and Severity Index (EASI) response. Approximately 200 adult participants ages 18 to less than 64 with moderate to severe AD who are current users of dupilumab and had a history of inadequate response to dupilumab will be enrolled at up to 130 sites worldwide.

The study is comprised of a 35-day Screening Period, an 8-week Open-Label Period 1 and a 24-week Open-Label Period 2 for participants that completed Period 1. Participants will receive upadacitinib oral tablets once daily or dupilumab subcutaneous (SC) injection every other week for 32 weeks and followed for 30 days.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

 Thousand Oaks, CA

Quincy, MA

Dallas, TX

Plymouth Meeting, PA

Austin, TX

Cypress, TX

Sugar Land, TX

Dawsonville, GA

Jacksonville, FL

Tampa, FL

Coral Springs - Oncology

Margate, FL

AbbVie

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Galderma

Find clinical trials for Eczema in Hanyang, Seoul

Related conditions:

Eczema trials near Hanyang, Seoul, KOR:

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)

Safety and Efficacy in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Find clinical trials for Eczema in .css-epvm6{white-space:nowrap;}Hanyang, Seoul

Related conditions:

Eczema trials near Hanyang, Seoul, KOR:

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)

Safety and Efficacy in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Find clinical trials for Eczema in Hanyang, Seoul